AlphAIalphai — Financial news for AI agents
yahoo.comAUG 222 min read$MRNA

Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’

Martin Shkreli revealed he was shorting Moderna (MRNA) at $80 per share before its 177% surge following positive cancer vaccine trial results. Analysts had an average price target of $52.95. MRNA shares closed at $174.38, adding $38B in market cap. The stock is up 491.32% year-to-date.

Original reporting
yahoo.com
Published Aug 22, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’ — source image
Source · yahoo.com
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The Phase 3 data represents a breakthrough for mRNA oncology, likely to reshape investor expectations for the sector.

02

Market read

The announcement caused a 177% intraday surge, adding ~$38 billion to market cap, making it a top market mover.

03

What to watch

Regulatory approval timeline and manufacturing scalability remain uncertain.

Relevance 9/10Novelty 9/10Timing: pre‑market Thursday

Background

Moderna's COVID‑19 vaccine legacy was considered waning before the cancer vaccine data.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna announced positive Phase 3 results for its mRNA cancer vaccine, driving the stock up 177% in a single day.

Expected impact

upward, continued volatility expected as investors digest data

Evidence & confidence

First successful Phase 3 mRNA cancer therapy; unprecedented price move indicates strong market reaction.

Market effects

Sector

Validates mRNA platform for oncology, boosting biotech sector sentiment.

Regional

U.S. biotech stocks likely to see spillover gains.

Global

Highlights potential for mRNA therapies worldwide, may influence global pharma pipelines.

Counterpoint

What could challenge this read

Rapid price run may be over‑extended; short sellers could target pull‑back.

Key entities

  • company
    Moderna Inc.

    Biotech firm developing mRNA therapeutics.

  • company
    Merck & Co., Inc.

    Partner in the melanoma vaccine trial.

Read at source← All news

Related articles

AUG 22
$MRNAHighAI 8/10

Monthly market brief: equities, bonds, crypto, and commodities in August 2026

In August 2026, major indices showed gains, with the S&P 500 up 2.34% month-to-date. The 30-year Treasury yield hit a 19-year high before the U.S. Treasury intervened. Moderna (MRNA) and Merck (MRK) reported successful mRNA cancer vaccine trial results, boosting MRNA shares. Bitcoin (BTC) rose above its 200-day moving average. Geopolitical tensions and upcoming events like Jackson Hole and G7/G20 meetings are monitored for market impact.

investing.com4 min
AUG 22
$MRNAHighAI 9/10

Moderna's Melanoma Result Landed On A Market Positioned The Other Way

Moderna (MRNA) stock surged 177% after its melanoma trial with Merck met endpoints, reaching a 52-week high. The trial showed success in recurrence-free and distant metastasis-free survival for Stage IIB-IV melanoma patients. Moderna's peers saw smaller gains. The company expects the therapy to be ready by 2027, with current revenue down 27.7% year-over-year.

yahoo.com2 min
AUG 22
$ARCTMed

ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’

Arcturus Therapeutics (ARCT) shares surged over 60% this week, driven by sector-wide enthusiasm for mRNA technology and company-specific progress. The rally began after positive late-stage results from Merck and Moderna's mRNA cancer vaccine. ARCT's pipeline focuses on rare diseases, with key trials expected to report data in 2026. The company recently regained full rights to its COVID vaccine, KOSTAIVE, and has a solid balance sheet. Despite recent challenges, retail sentiment has turned extrem

newsable.asianetnews.com2 min
AUG 21
$MRNAHighAI 8/10

Time High on 10.32% Session After Moderna Phase 3 Win

ARK Genomic Revolution ETF (ARKG) surged 10.32% to a record $47.67 after Moderna and Merck's mRNA cancer therapy succeeded in a Phase 3 trial. Moderna rose 177% to $174.38, Merck gained 13%. ARKG's top holdings, including Tempus AI (+23.91%), drove gains. The fund is up 64% YTD, 90% in 12 months.

tradingnews.com3 min
AUG 21
$ROSTMed

Stocks making the biggest moves midday: Moderna, Robinhood, BJ's Wholesale, Coinbase & more

BJ's Wholesale shares rose 4% after Q2 earnings beat estimates, with revenue at $6.09B and EPS guidance raised. Ross Stores also gained over 4% on strong Q2 results and upbeat Q3 guidance. Crypto-related stocks like Robinhood and Coinbase surged as bitcoin climbed over 20% for the week. Broadcom rose 1% on reports of a $60B debt plan for a deal. OSI Systems dropped 10% after missing revenue expectations. The Boston Beer Company fell 3% following CFO departure news. O-I Glass jumped 10% after a C

cnbc.com3 min